冠心病的治疗.pptxVIP

Antiathosderotic;Introduction Atherosclerosis (AS) Ross R: Atherosclerosis is an inflammatory disease;,;正常管腔;冠心病（动脉粥样硬化）的危险因素;AS形成过程:;monocyte;Vessel Lumen;Vessel Lumen;Vessel Lumen;Vessel Lumen;NetEak;Treatment;Section 1;1. The composition of blood lipid;我国人群血脂的年龄和性别分布;2. The Composition and Function of Lipoprotein;【The size of lipoprotein 】;脂蛋白的种类、纽J戈及功能;[physiological function of lipoprotein];[clinical meaning of lipoprotein ];3. Metabolic abnormality of lipid;The aims level of modulating lipids;増高的血脂 ___;[Type of Hyperlipoproteinemia];The commonly used drugs;1. Statins (他汀类) (Inhibitors of HMG-CoA reductase);History;Pharmacological effects;Mechanism;【Synthesis of cholesterol ];【Statins 】;血液;Non lipidemic-modulating action;Pharmacokinetics HMG-CoA还原薦抑制剂药代动丿J学比较;Clinical uses;Clinical experiment;Adverse reactions;拜斯亭事件;横纹肌溶解症;Drug interaction;汤 Net Ease;2. Bile acid-binding resins （胆汁酸结合树脂）;Pharmacological effects:;LDL;Clinical uses;3- Niacins;Pharmacological actions;Mechanism of Action;4.Fibrates （贝特类）;Pharmacological Actions;Mechanism:;;Clinical uses;5. Lp(a)-lowering Drugs Elevation of blood Lp(a) is a independent risk factor, and a risk factor of restenosis after percutaneous transluminal coronary angioplasty;降Lp(a)的药物;Section 2 Antioxidants;1. OX-LDL促进AS病变发生和发展;2.Lp(a)和VLDL被氧化可增强其致AS作岸;Probucol （普罗布考）;Clinical uses;Section 3;COOH \AAAAJAcooh VTO/W0011;n-3 type PUFAs;Pharmacological effects;Clinical use;n-6 type PuFA Evening primrose oil (月见草油) linoleic acid 70%, y-linolenic acid 6%-9%;THE END